US Broker Ratings

Immunocore Holdings plc (IMCR) Stock Analysis: A Biotech With Over 100% Potential Upside

Immunocore Holdings plc (NASDAQ: IMCR) stands out in the biotechnology sector, not just for its innovative approach to immunotherapies but also for the striking potential upside it offers to investors...

Arrowhead Pharmaceuticals (ARWR) Investor Outlook: Exploring the 27.49% Upside Potential

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), a beacon in the biotechnology industry, has been drawing attention with its remarkable growth trajectory and innovative pipeline. With a market capitalization of $8.94 billion,..

Astrana Health Inc. (ASTH) Stock Analysis: Exploring a Massive 89.92% Potential Upside

Astrana Health Inc. (NASDAQ: ASTH), a prominent player in the U.S. healthcare sector, has recently captured the attention of investors with its impressive growth trajectory and substantial potential upside. With..

Neogen Corporation (NEOG) Stock Analysis: Navigating a 6.64% Potential Upside Amidst Financial Challenges

Neogen Corporation (NASDAQ: NEOG), a prominent player in the healthcare sector’s diagnostics and research industry, is positioning itself for growth despite current financial hurdles. With a market capitalization of $2.38..

Dyne Therapeutics, Inc. (DYN) Stock Analysis: Exploring a 151% Upside Potential in Biotech

Dyne Therapeutics, Inc. (NASDAQ: DYN), a pioneering clinical-stage biotechnology company focusing on neuromuscular diseases, is generating buzz among investors with its robust growth potential. With a market capitalization of $2.56..

IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: Exploring a 65% Upside Potential in Precision Oncology

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a notable player in the biotech sector, specializes in precision medicine oncology with a focus on developing targeted therapeutics. With a current market cap of..

Teladoc Health, Inc. (TDOC) Stock Analysis: Unpacking a 92% Potential Upside for Investors

Teladoc Health, Inc. (NYSE: TDOC), a leading player in the virtual healthcare sector, presents an intriguing investment opportunity, boasting a potential upside of 92.08% from its current stock price of..

Vera Therapeutics, Inc. (VERA) Stock Analysis: Unraveling the 78% Potential Upside in Biotechnology

Vera Therapeutics, Inc. (NASDAQ: VERA), a biotechnology company at the forefront of developing transformative treatments for serious immunological diseases, presents a compelling opportunity for investors seeking substantial upside potential. With..

Adaptive Biotechnologies (ADPT) Stock Analysis: Unpacking a 30% Upside Potential in Biotechnology

Adaptive Biotechnologies Corporation (ADPT), a prominent player in the healthcare sector, stands at the forefront of the biotechnology industry with its cutting-edge immune medicine platform. Headquartered in Seattle, Washington, this..

Kymera Therapeutics, Inc. (KYMR) Stock Analysis: 41.75% Upside Potential with Robust Analyst Ratings

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a notable player in the biotechnology sector, is capturing attention with its innovative approach to drug development. Specializing in small molecule therapeutics that leverage the..

Phreesia, Inc. (PHR) Stock Analysis: Unlocking a Potential Upside of Nearly 137%

Phreesia, Inc. (PHR) is a key player in the healthcare technology sector, providing an innovative Software-as-a-Service (SaaS) platform that streamlines patient intake and payment processes. As the healthcare industry increasingly..

NewAmsterdam Pharma (NAMS) Stock Analysis: Potential 41% Upside Beckons Investors Despite Current Challenges

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS), a Netherlands-based biopharmaceutical firm, is capturing investor interest with its promising yet challenging financial landscape. Specializing in the development of therapies for metabolic diseases,..

ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Exploring a Potential 225.8% Upside in the Biotech Sector

As ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) captures investor attention, the biotech firm presents a compelling case for those looking to capitalize on significant potential upside. Specializing in innovative treatments for..

Celldex Therapeutics, Inc. (CLDX) Stock Analysis: A Bold Bet with 131.99% Potential Upside

Celldex Therapeutics, Inc. (NASDAQ: CLDX) stands out in the biotechnology sector, leveraging its innovative approach in developing therapeutic antibodies targeting severe inflammatory and autoimmune diseases. With a market capitalization of..

Privia Health Group, Inc. (PRVA) Stock Analysis: A Promising 39.57% Upside Potential

Privia Health Group, Inc. (NASDAQ: PRVA) is attracting significant attention from investors in the healthcare sector due to its robust growth prospects and impressive analyst ratings. As a leader in..

LifeStance Health Group, Inc. (LFST) Stock Analysis: Exploring a 28% Upside Potential

LifeStance Health Group, Inc. (NASDAQ: LFST), a prominent player in the healthcare sector, specifically within the medical care facilities industry, is gaining considerable attention from investors looking for growth opportunities...

DENTSPLY SIRONA Inc. (XRAY) Stock Analysis: A High-Yield Dividend Play Amidst Challenging Metrics

DENTSPLY SIRONA Inc. (NASDAQ: XRAY), a prominent player in the medical instruments and supplies industry, stands out with its attractive dividend yield of 4.94%. However, investors should weigh this income..

Omnicell, Inc. (OMCL) Investor Outlook: Exploring a Potential 57.34% Upside

Omnicell, Inc. (NASDAQ: OMCL), a prominent player in the healthcare sector, is capturing investor attention with its compelling growth potential amidst a challenging market landscape. As a leading provider of..

CG Oncology, Inc. (CGON) Stock Analysis: A 55% Upside Potential in the Biotech Sector

CG Oncology, Inc. (NASDAQ: CGON), a promising player in the biotechnology sector, is capturing the attention of investors with a compelling storyline of innovation and potential growth. Specializing in bladder-sparing..

Kiniksa Pharmaceuticals Interna (KNSA) Investor Outlook: Eyeing a 21% Upside with Strong Buy Ratings

Kiniksa Pharmaceuticals Interna (NASDAQ: KNSA) has been capturing the attention of investors with its compelling growth story and impressive market performance. As a prominent player in the healthcare sector, specifically..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds